Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 卫生和社会工作业
Company Introduction 通策医疗股份有限公司（股票代码：600763SH）是一家以医疗服务为主营业务的主板上市公司。公司目前拥有多家口腔医疗、健康生殖医疗机构，致力于成为中国领先的综合医疗平台。 通策医疗在全国各地开设了近30家口腔医院，是中国大型口腔医疗连锁机构。公司旗下杭州口腔医院创建于1952年，是世界上较大的口腔医院。为加快全国布局，通策医疗参与设立了口腔医疗投资基金，投资建设北京、武汉、重庆、成都、广州和西安六家大型口腔医院。 由通策与2010年诺贝尔生理学或医学奖获得者、“试管婴儿之父”RobertEdwards创立的体外受精试管婴儿治疗中心剑桥波恩共同打造昆明波恩生殖中心已投入运营，各项指标达到国际先进水平。 通策与杭州医学院达成战略合作，联合创办杭州医学院妇幼、口腔方面的二级学院，并开展产学研深度合作。 通策医疗作为中国医药具有竞争力上市公司50强企业，连续五年入选“福布斯中国最具潜力中小企业100强”。
Main Business 医疗服务
Legal Representative 王毅
Top Executives
董事长：王毅
董事：王维倩,黄浴华,王毅,吕紫萱
独立董事：刘曙峰,张森泉,王绪强,李敏
Top 5 Shareholder
Shareholder name Nature Holding Date
杭州宝群实业集团有限公司流通A股33.89%30/09/2024
中国工商银行股份有限公司－中欧医疗健康混合型证券投资基金流通A股3.56%30/09/2024
鲍正梁流通A股3.13%30/09/2024
中国银行股份有限公司－华宝中证医疗交易型开放式指数证券投资基金流通A股2.30%30/09/2024
浙江存济医疗教育基金会流通A股2.18%30/09/2024
Company Secretary 张华
Solicitors 北京国证律师事务所
Auditors 北京会计师事务所
Tel No 0571-88868808;0571-88970616
Fax No 0571-87283502
Website www.tcmedical.com.cn
Email zhanghua@eetop.com;zhangli@eetop.com
Company Address
Register: 浙江省杭州市平海路57号
Office: 浙江省杭州市灵溪北路21号合生国贸中心5号楼10楼
Listing Date 30/10/1996
Shares Capital
Shares Capital: 447,289,117
Total A Share: 447,289,117
Listed A Share: 447,289,117
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.560
DPS(RMB)* ¥ 0.436
NBV Per Share(RMB)* ¥ 11.867
Market Capitalization(RMB) 21.837B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.